Allen Hu, MD
Ophthalmology · Hagerstown, MDNPI 1235315268
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $280,873 of the $379,289 with a category attached, or 74.1%. It is spread thinly across 34 manufacturers, the largest accounting for just 22.2%. Among ophthalmology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 422 payments — averaging $898.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$84K
- Apellis Pharmaceuticals, Inc.$66K
- Ocular Therapeutix, Inc.$58K
- Genentech USA, Inc.$46K
- Baxter Healthcare$29K
- F. Hoffmann-la Roche AG$28K
- plus $67K from 28 others
Across 3,025 payments — averaging $15,703 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$18.1M
- Roche TCRC, Inc.$9.7M
- Ocular Therapeutix, Inc.$7M
- Bayer$4.2M
- Apellis Pharmaceuticals, Inc.$2.8M
- Regeneron$2.5M
- plus $3.2M from 10 others
What the payments were for
- Consulting fees$280,87374%
- Speaking & faculty fees$78,41521%
- Travel & lodging$6,7352%
- Food & beverage$13,2463%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 35 | $84,033 |
| Apellis Pharmaceuticals, Inc. | 54 | $66,268 |
| Ocular Therapeutix, Inc. | 47 | $58,271 |
| Genentech USA, Inc. | 74 | $46,479 |
| Baxter Healthcare | 24 | $28,830 |
| F. Hoffmann-la Roche AG | 6 | $28,261 |
| Astellas Pharma US Inc | 40 | $27,860 |
| Janssen Global Services, LLC | 14 | $11,915 |
| Welch Allyn | 2 | $6,410 |
| Harrow Eye, LLC | 10 | $5,238 |
| Regeneron | 5 | $4,208 |
| GSK | 1 | $1,950 |
| Notal Vision, Inc. | 2 | $1,727 |
| Cardinal Health 108 LLC | 1 | $1,575 |
| Coherus Oncology, Inc. | 4 | $1,425 |
| Boehringer Ingelheim International GmbH | 2 | $934 |
| Biogen | 13 | $834 |
| AbbVie(2 entities) | 30 | $657 |
| Alimera Sciences, Inc. | 12 | $458 |
| Bausch & Lomb Americas Inc. | 11 | $433 |
| Abbott | 7 | $308 |
| Regeneron Healthcare Solutions, Inc. | 7 | $291 |
| Eyepoint US, Inc. | 3 | $224 |
| ANI Pharmaceuticals, Inc. | 3 | $178 |
| Neurotech Pharmaceuticals, Inc. | 1 | $139 |
| Astellas Pharma Global Development | 1 | $127 |
| Novartis | 5 | $87 |
| Thrombogenics, Inc. | 1 | $34 |
| Spark Therapeutics, Inc. | 2 | $31 |
| Mallinckrodt Enterprises LLC | 1 | $30 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $22 |
| Amgen | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$40,529
- Hillrom - RetinaVue 700 Imager$28,830
- Hillrom - RetinaVue Network$28,830
- Izervay$27,237
- Syfovre$15,473
- Lucentis$11,667
- RetinaVue Network$6,210
- IHEEZO$5,064
- SUSVIMO$4,268
- EYLEA HD$3,934
- BLENREP$1,950
- YUTIQ$437
- EYLEA$402
- Cimerli$264
- XIPERE$246
- iExaminer Image Reader$200
- Iluvien$157
- VISUDYNE$124
- OZURDEX$124
How this compares
$379,289 in reported general payments places this provider in the 95th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CombiganBrimonidine Tartrate/Timolol | 20 | $9,431 |
| Prednisolone Acetate | 196 | $6,056 |
| ProlensaBromfenac Sodium | 11 | $3,942 |
| NevanacNepafenac | 12 | $3,766 |
| Brimonidine Tartrate | 40 | $2,866 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 17 | $2,841 |
| Ofloxacin | 93 | $1,031 |
| Timolol Maleate | 67 | $587 |
| Ketorolac Tromethamine | 30 | $517 |
| Atropine Sulfate | 16 | $440 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 40 | $407 |
| Latanoprost | 43 | $326 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 16 | $259 |
| Dorzolamide Hcl | 19 | $252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan | $657 | $9,43120 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $22 | $3,94211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 493 ophthalmology providers in Maryland.
Other ophthalmology in Hagerstown
- David WarrowHagerstown$78K
- Jay BerdiaHagerstown$38K
- John WroblewskiHagerstown$14K
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- Peter McDonnellBaltimore$1.4M
- Esen AkpekBaltimore$782K
- Lisa FeulnerBel Air$434K
- Susan BresslerLutherville$341K
- Renee BovelleGlenn Dale$292K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.